36 unknown, 10 completed, 2 not yet recruiting. 48 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Unknown 36, Completed 10, Not yet recruiting 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Endostar: new trials by email Literature Review of Endostar trials Research Report on Endostar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC Stereotactic Radiation Therapy, Envafolimab, Endostar - Non Small Cell Lung Cancer, Lung Neoplasms | Phase 2 | Not yet recruiting | The First People's Hospital of Lianyungang | 61 | 2026-10-01 | 2026-09-14 |
| Local Injection and Systemic Therapy in the Treatment of NSCLC. Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5 - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 84 | 2024-10-08 | 2024-10-01 |
| Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors Envafolimab Injection, Endostar - Gastrointestinal Neoplasms | Phase 2 | Unknown | Nanjing First Hospital, Nanjing Medical University | 16 | 2024-02-21 | 2024-03-08 |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Envafolimab, Endostar, Nab paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2022-04-01 | 2022-03-28 |
| Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC Envafolimab, Endostar - Lung Neoplasms | Phase 2 | Unknown | The First People's Hospital of Lianyungang | 40 | 2022-03-01 | 2023-06-22 |
| Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Endostar - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Jiangxi Provincial Cancer Hospital | 30 | 2021-07-28 | 2022-01-04 |
| Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma Endostar, Toripalimab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Unknown | Fudan University | 43 | 2020-04-01 | 2023-06-22 |
| Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC Camrelizumab - Non-small Cell Lung Cancer | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 52 | 2019-12-31 | 2020-03-10 |
| CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer Radiotherapy, Endostar, Cisplatin - Cervical Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 82 | 2019-08-01 | 2019-10-10 |
| Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors second-line chemotherapy, Recombinant human endostatin - Head and Neck Neoplasms | Phase 2 | Unknown | Sun Yan | 53 | 2019-07-29 | 2020-10-23 |
| Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma Endostar, Cisplatin, Docetaxel - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Jiangsu Cancer Institute & Hospital | 73 | 2019-06-01 | 2019-04-30 |
| Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer Docetaxel, Nedaplatin, Endostar - Esophageal Cancer | Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 186 | 2018-11-01 | 2018-08-28 |
| Rh-Endostatin (Endostar®) Continuous Intravenous Infusion Endostar, Docetaxel, Carboplatin - Lung Cancer | Phase 2 | Unknown | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 50 | 2018-10-01 | 2018-10-17 |
| Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis Endostar, standard SRILI treatment - Radiation Pneumonitis, Endostatin | Phase 2 | Completed | Xinqiao Hospital of Chongqing | 126 | 2018-09-01 | 2024-02-23 |
| Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas Irinotecan, DDP, Endostar - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Fudan University | 52 | 2017-05-04 | 2025-07-23 |
| Endostar Combined With Chemotherapy for Stage â…£ Soft Tissue Sarcoma Endostar, Placebo, AIM regimen / GT regimen - Soft Tissue Sarcoma, Adult, Stage IIB | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 52 | 2017-05-01 | 2019-12-26 |
| Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma Endostar, DDP - Cervical Carcinoma | Phase 2 | Completed | Yong Zhang,MD | 120 | 2017-04-20 | 2025-07-29 |
| Endostar First-line Treatment of Advanced NSCLC Endostar, Gemcitabine, Cisplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | China Medical University, China | 150 | 2017-04-01 | 2017-04-21 |
| Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC endostar, Placebos, radiotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2017-02-21 | 2018-08-03 |
| Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma recombinant human endostatin - Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 70 | 2016-10-01 | 2017-03-29 |
Showing 20 of 48. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Nasopharyngeal Carcinoma (6) · Lung Neoplasms (4) · Colorectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Esophageal Neoplasms (2) · Lymphoma, T-Cell, Peripheral (2) · Melanoma (2) · Nasopharyngeal Neoplasms (2) · Sarcoma (2) · Uterine Cervical Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1)
Fudan University (5) · Zhejiang Cancer Hospital (5) · Jiangsu Simcere Pharmaceutical Co., Ltd. (3) · First Affiliated Hospital of Guangxi Medical University (2) · Peking University Cancer Hospital & Institute (2) · Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd (2) · Simcere Pharmaceutical Co., Ltd (2) · Sun Yat-sen University (2) · The First People's Hospital of Lianyungang (2) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · China International Medical Foundation (1) · China Medical University, China (1) · China Three Gorges University, Yichang, China (1) · Chinese Academy of Medical Sciences (1) · Henan Cancer Hospital (1)
China (43)
Xiaodong Jiang, MD (2) · Bin Li (1) · Fei Han, M.D., Ph.D. (1) · Guoliang Jiang, MD (1) · Hanmei Lou, PHD (1) · Hongbo Wu, M.D. (1) · Jian Fang (1) · Jilong Yang, M.D., Ph.D. (1) · Junning Cao, MD (1) · Li Liang, MD (1) · Liming Zhu, MD (1) · Lin Yang, MD (1) · Ming Chen, Doctor (1) · Ming Fan, MD (1) · Peng Yuan, MD (1)
PMID 15172975, PMID 22099051, PMID 22209574, PMID 22496834, PMID 22562140, PMID 23670576, PMID 25198661, PMID 25244494, PMID 25497558, PMID 26434908, PMID 27067521, PMID 35380726, PMID 41014160, PMID 41049580